Activation of kappa opioid receptors decreases synaptic transmission and inhibits long-term potentiation in the basolateral amygdala of the mouse

European Journal of Pain

Volumn 13, Issue 2, 2009, Pages 124-129

  Huge, Volker ^a,b   Rammes, Gerhard ^a,c   Beyer, Antje ^b   Zieglgänsberger, Walter ^a   Azad, Shahnaz C ^a,b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Amygdala; Electrophysiology; Kappa opioid receptor agonists; LTP; Synaptic transmission

Indexed keywords

KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; KAPPA OPIATE RECEPTOR ANTAGONIST;

ACTION POTENTIAL; AMPLITUDE MODULATION; AMYGDALOID NUCLEUS; ANIMAL TISSUE; ARTICLE; BRAIN SLICE; C57BL 6 MOUSE; C57BL MOUSE; CONTROLLED STUDY; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; FREQUENCY MODULATION; IN VITRO STUDY; LONG TERM POTENTIATION; MALE; MOUSE; NERVE CELL PLASTICITY; NEUROPHYSIOLOGY; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; SENSORY NERVE; SYNAPTIC TRANSMISSION;

3,4-DICHLORO-N-METHYL-N-(2-(1-PYRROLIDINYL)-CYCLOHEXYL)-BENZENEACETAMIDE, (TRANS)-ISOMER; AMYGDALA; ANALGESICS, NON-NARCOTIC; ANIMALS; CHRONIC DISEASE; ELECTRIC STIMULATION; ELECTROPHYSIOLOGY; EMOTIONS; EXTINCTION, PSYCHOLOGICAL; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; NALTREXONE; PAIN; RECEPTORS, OPIOID, KAPPA; SYNAPTIC TRANSMISSION;

EID: 58149361376     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2008.03.010     Document Type: Article

References (34)

1. Azad S.C., Huge V., Schops P., Hilf C., Beyer A., Dodt H.U., et al. Endogenous cannabinoid system. Effect on neuronal plasticity and pain memory. Schmerz 19 (2005) 521-527
2. Azad S.C., and Zieglgansberger W. What do we know about the state of chronic pain?. Schmerz 17 (2003) 441-444
3. Choi D.S., Choi D.Y., Whittington R.A., and Nedeljkovic S.S. Sudden amnesia resulting in pain relief: the relationship between memory and pain. Pain 132 (2007) 206-210
4. Drake C.T., Terman G.W., Simmons M.L., Milner T.A., Kunkel D.D., Schwartzkroin P.A., et al. Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters. J Neurosci 14 (1994) 3736-3750
5. Geha P.Y., Baliki M.N., Chialvo D.R., Harden R.N., Paice J.A., and Apkarian A.V. Brain activity for spontaneous pain of postherpetic neuralgia and its modulation by lidocaine patch therapy. Pain 128 (2007) 88-100
6. Hadjipavlou G., Dunckley P., Behrens T.E., and Tracey I. Determining anatomical connectivities between cortical and brainstem pain processing regions in humans: a diffusion tensor imaging study in healthy controls. Pain 123 (2006) 169-178
7. Helmstetter F.J., Bellgowan P.S., and Poore L.H. Microinfusion of mu but not delta or kappa opioid agonists into the basolateral amygdala results in inhibition of the tail flick reflex in pentobarbital-anesthetized rats. J Pharmacol Exp Ther 275 (1995) 381-388
8. Ikeda H., Heinke B., Ruscheweyh R., and Sandkuhler J. Synaptic plasticity in spinal lamina I projection neurons that mediate hyperalgesia. Science 299 (2003) 1237-1240
9. Jamensky N.T., and Gianoulakis C. Content of dynorphins and kappa-opioid receptors in distinct brain regions of C57BL/6 and DBA/2 mice. Alcohol Clin Exp Res 21 (1997) 1455-1464
10. Kauer J.A., and Malenka R.C. Synaptic plasticity and addiction. Nat Rev Neurosci 8 (2007) 844-858
11. Lahti R.A., VonVoigtlander P.F., and Barsuhn C. Properties of a selective kappa agonist, U-50,488H. Life Sci 31 (1982) 2257-2260
12. LeDoux J.E. Emotion circuits in the brain. Ann Rev Neurosci 23 (2000) 155-184
13. Malenka R.C., and Nicoll R.A. Long-term potentiation - a decade of progress?. Science 285 (1999) 1870-1874
14. Manning B.H., Merin N.M., Meng I.D., and Amaral D.G. Reduction in opioid- and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. J Neurosci 21 (2001) 8238-8246
15. Mansour A., Fox C.A., Akil H., and Watson S.J. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18 (1997) 22-29
16. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 418 (2002) 530-534
17. Nakagawa T., Katsuya A., Tanimoto S., Yamamoto J., Yamauchi Y., Minami M., et al. Differential patterns of c-fos mRNA expression in the amygdaloid nuclei induced by chemical somatic and visceral noxious stimuli in rats. Neurosci Lett 344 (2003) 197-200
18. Narita M., Kaneko C., Miyoshi K., Nagumo Y., Kuzumaki N., Nakajima M., et al. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31 (2006) 739-750
19. Nestler E.J. Common molecular and cellular substrates of addiction and memory. Neurobiol Learn Mem 78 (2002) 637-647
20. Neugebauer V., Li W., Bird G.C., and Han J.S. The amygdala and persistent pain. Neuroscientist 10 (2004) 221-234
21. Paulson P.E., Casey K.L., and Morrow T.J. Long-term changes in behavior and regional cerebral blood flow associated with painful peripheral mononeuropathy in the rat. Pain 95 (2002) 31-40
22. Price D.D. Psychological and neural mechanisms of the affective dimension of pain. Science 288 (2000) 1769-1772
23. Rammes G., Steckler T., Kresse A., Schutz G., Zieglgansberger W., and Lutz B. Synaptic plasticity in the basolateral amygdala in transgenic mice expressing dominant-negative cAMP response element-binding protein (CREB) in forebrain. Eur J Neurosci 12 (2000) 2534-2546
24. Rodrigues S.M., Schafe G.E., and LeDoux J.E. Molecular mechanisms underlying emotional learning and memory in the lateral amygdala. Neuron 44 (2004) 75-91
25. Rogan M.T., and LeDoux J.E. Emotion: systems, cells, synaptic plasticity. Cell 85 (1996) 469-475
26. Sah P., Faber E.S.L., Lopez de armentia M., and Power J. The amygdaloid complex: anatomy and physiology. Physiol Rev 83 (2003) 803-834
27. Sandkuhler J. Learning and memory in pain pathways. Pain 88 (2000) 113-118
28. Shin M.S., and Helmstetter F.J. Antinociception following application of DAMGO to the basolateral amygdala results from a direct interaction of DAMGO with Mu opioid receptors in the amygdala. Brain Res 1064 (2005) 56-65
29. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., et al. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J 17 (1998) 886-897
30. Tanimoto S., Nakagawa T., Yamauchi Y., Minami M., and Satoh M. Differential contributions of the basolateral and central nuclei of the amygdala in the negative affective component of chemical somatic and visceral pains in rats. Eur J Neurosci 18 (2003) 2343-2350
31. Tershner S.A., and Helmstetter F.J. Antinociception produced by mu opioid receptor activation in the amygdala is partly dependent on activation of mu opioid and neurotensin receptors in the ventral periaqueductal gray. Brain Res 865 (2000) 17-26
32. Treede R.D., Klein T., and Magerl W. Pain memory and central sensitization in humans. In: Flor H., Kalso E., and Dostrovsky J. (Eds). Proceedings of the 11th world congress on pain. Progress in pain research and management vol. 25 (2006), IASP Press, Seattle 251-267
33. Zieglgansberger W., and Tolle T.R. The pharmacology of pain signalling. Curr Opin Neurobiol 3 (1993) 611-618
34. Zimmermann M. Pathobiology of neuropathic pain. Eur J Pharmacol 429 (2001) 23-37